METASTATIC COLORECTAL TREATMENT COSTS OF USING TARGETED DRUGS IN SECOND AND FURTHER LINES THERAPY
Targeted drugs are recommended for treatment of metastatic colorectal cancer. Second and further lines therapy options include anti-EGFR therapy, eligible for patients with wild-type KRAS (cetuximab and panitumumab), and relatively new drug - regorafenib, which could be used for all patients.The aim...
Saved in:
Main Authors: | N. A. Avxentyev (Author), E. V. Derkach (Author), E. A. Pyadushkina (Author), M. D. Ter-Ovanesov (Author) |
---|---|
Format: | Book |
Published: |
IRBIS LLC,
2016-09-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Cost-effectiveness analysis of encorafenib and binimetinib combination as first-line treatment for metastatic or unresectable <i>BRAF</i> V600-mutated metastatic melanoma in Russia
by: N. A. Avxentyev, et al.
Published: (2023) -
Molecularly targeted drugs for metastatic colorectal cancer
by: Cheng YD, et al.
Published: (2013) -
Pharmacoeconomic analysis of treatment with nilotinib as the second line therapy in patients with chronic myeloid leukemia
by: N. A. Avxentyev, et al.
Published: (2018) -
Molecular targeted therapy for metastatic colorectal cancer: current and evolving approaches
by: Furong Li, et al.
Published: (2023) -
A phase I/II study of biweekly capecitabine and irinotecan plus bevacizumab as second-line chemotherapy in patients with metastatic colorectal cancer
by: Suenaga M, et al.
Published: (2015)